Besides treating acute flares, the management of SLE should aim at preventing organ
damage accrual and drug-associated harms, improving health-related quality of life and …

SLE is a chronic autoimmune rheumatic disorder of high heterogeneity in clinical
presentation, treatment response and prognosis. Long-term outcomes in SLE have been …

Objectives To compare the efficacy to prevent flares of maintenance versus withdrawal of 5
mg/day prednisone in systemic lupus erythematosus (SLE) patients with clinically quiescent …

Objective In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC)
exposure are known to contribute to irreversible organ damage. We aimed to examine the …

Systemic lupus erythematosus (SLE) is an immune-mediated multi-systemic disease
characterized by a wide variability of clinical manifestations and a course frequently subject …

Objectives There is an unmet need for accurate and user-friendly definitions of systemic
lupus erythematosus (SLE) disease activity and remission. We aimed to derive and validate …

Treat-to-target strategies have changed the approach to management of many chronic
conditions, with improvements in patient outcomes. The key to success of treat to target is …

Objectives Patients with systemic lupus erythematosus (SLE) are usually treated with
glucocorticosteroids even during periods of clinically quiescent disease. A recent study …

Background Connective tissue disease associated interstitial lung disease (CTD-ILD) is
associated with decreased quality of life and high mortality risk. Outcome and treatment …

Objectives To evaluate what proportion of patients fulfil the DORIS definition of remission,
the definition of lupus low disease activity state (LLDAS) and LLDAS with a glucocorticoid …